AstraZeneca Deploys Decision Lens for Future Drug Screening and Selection
Prioritization Software From Decision Lens Assisting Pharmaceutical Giant in Creating Company-Wide Model to Evaluate and Select Drug Portfolios
(firmenpresse) - ARLINGTON, VA -- (Marketwired) -- 10/02/14 -- Decision Lens will assist key pharmaceutical decision makers in screening and selecting future drugs currently in research and development (R&D) at AstraZeneca. , the leading provider of cloud-based, strategic prioritization software, announced today that it has been chosen by AstraZeneca to prioritize its company-wide portfolio of prescription medicines over a two-year period. AstraZeneca, a global biopharmaceutical company, specializes in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.
The Decision Lens platform will aid AstraZeneca and its subsidiary, MedImmune, with reviewing and prioritizing the firms'' investments across the therapeutic area portfolios. Leveraging considerations such as estimated financial returns, strategic alignment, and time-to-deliver, Decision Lens will help uncover insights about the potential benefits and risks of the drugs in the portfolios to key stakeholders.
"Selecting which drugs to continue to research and eventually take to market becomes a highly complex decision, both from a medical and a business standpoint, which is why Decision Lens'' unique prioritization platform is able to generate multiple scenarios based on the collective input of key stakeholders at AstraZeneca," said John Kealey, CEO of Decision Lens.
The Decision Lens platform is built on a flexible, Web Services architecture. The Software as a Service (SaaS) delivery model can reduce standup time to a matter of hours, and allows it to run in standard Web browsers such as Internet Explorer, Chrome, Mozilla and Safari.
Decision Lens software is used across government and commercial organizations for better prioritization and resource allocation. Key clients include Amtrak, Maryland Transit Administration, Shell, the Joint Chiefs of Staff, the U.S. Navy, Air Force, and Army, the Kansas City Chiefs, and the Washington Metropolitan Area Transit Authority (WMATA).
Decision Lens () develops progressive optimization software solutions that allow organizations to make complex decisions more effectively and efficiently. Our collaborative software platform structures decisions, quantifies intangible factors, and evaluates choices that enable organizations to reach their goals.
Decision Lens improves the speed and quality of prioritization and resource optimization, while maximizing returns, and provides accountability and transparency for how decisions are made.
For more information contact Decision Lens at 703-399-2100 or visit .
Colleen Johnson
703-253-6129
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2014 - 07:17 Uhr
Sprache: Deutsch
News-ID 1307032
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
ARLINGTON, VA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 113 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AstraZeneca Deploys Decision Lens for Future Drug Screening and Selection
"
steht unter der journalistisch-redaktionellen Verantwortung von
Decision Lens (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
